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Evidence for the approach to the diagnostic evaluation of squamous 
cell carcinoma occult primary tumors of the head and neck 
 
 
 
 
Abstract: 
 
Metastases to the cervical lymph nodes from a occult primary (CUP) of head and neck 
squamous carcinomas has been increasing in presentation (HNSCC). Modern diagnostic 
workup, including clinical evaluation, conventional imaging, FDG-PET/CT and 
panendoscopy/tonsillectomy enables detection of the primary site in over half of all cases, 
and is associated with significantly improved survival rates. Recent studies have 
demonstrated the utility of novel molecular pathology and transoral surgical techniques in 
improving diagnosis and treatment. We present a new, evidence-based protocol 
incorporating these novel diagnostic modalities. It aims to identify the site of the primary 
tumor, and determine the stage of the disease, including extranodal extension. This 
information can personalise treatment recommendations, rationalise combinations of 
treatment modalities, and thereby potentially minimise toxicity and improving functional 
outcomes.  
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Introduction 
 
The carcinoma of unknown primary in the head and neck (CUP) occurs when a 
patient presents with clinically-evident cervical lymphadenopathy, but where a primary 
tumor cannot be identified by thorough medical history, clinical examination and non-
invasive and invasive diagnostic workup [1]. 
The identification of the primary site by modern functional imaging has significantly 
reduced the prevalence of true CUP [2]. In the past, only about 1-7% of all head and neck 
cancer patients present with metastases to the lymph nodes as the only clinical evidence of 
the disease [3-5]. This appears to be is increasing in incidence due to the increasing human 
papillomavirus-related oropharyngeal cancer [5]. The natural history of the development of 
CUP remains unclear. Potential reasons for the inability to detect the primary site may 
include small tumour volume, hidden location (e.g. tonsillar crypt), slow growth rate, and/or 
possible involution of the primary tumor, thereby hindering its recognition[6, 7].  
Several guidelines, consensus statements, and literature reviews have been 
published describing the diagnostic and therapeutic approach to CUP in the last decade [8-
10]. However, recently there has been a considerable amount of new and essential data 
published on novel diagnostic approaches, including the role of Human papillomavirus (HPV) 
detection and the utility of transoral minimally-invasive procedures. Our aim here is to 
present an evidence-based algorithm for the diagnosis and treatment of patients with CUP, 
that incorporates recent developments. 
 
Objectives: 
 
The principal objectives of the diagnostic evaluation of the patient with CUP are to 
identify the location of the primary tumor, to reliably determine the histology, to ascertain 
the extent of locoregional disease (including nodal extranodal extension), and to exclude 
distant metastases. The other important consideration for the diagnostic workup should be 
the utilization of the shortest and the least invasive pathway to achieve diagnosis and 
treatment, with the least morbidity and the highest cost-effectiveness [9].  
A retrospective study of 236 patients with an initial presentation of CUP 
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demonstrated ultimate detection of a primary tumour after investigation in 53% of cases.  
Approximately 88% of these were oropharyngeal primaries (equally divided between the 
base of tongue and tonsil). The likelihood of a biopsy-proven primary decreased significantly 
in patients with no findings on examination and radiology, compared to those with positive 
findings on both (29% vs. 64% respectively)[11].  
Identification of the primary site is crucial as it helps direct therapy and has been 
reported by some studies to be associated with better prognosis and survival.  A matched 
paired retrospective analysis by Davis  (n=22), demonstrated significantly improved survival 
in patients with CUP where the primary tumour was subsequently identified, compared to 
those where it was not (HR = 0.125; 95% CI, 0.019–0.822; P = .030). This may be in part 
because lesions that were identified were more likely to be HPV positive[12]. Similarly, Haas 
et al. reported 100% 3-year survival in the eight patients whose oropharyngeal primary was 
identified compared to 58.8% for the 34 patients with a persistent "occult primary" (n=34) 
[13].  
 
TNM staging: 
 
In the American Joint Cancer Commission (AJCC) [14] and Union for International 
Cancer Control (UICC) 8th Editipn TNM Staging Manual [15], substantial changes have been 
introduced to the staging of patients with  CUP.  Previously, CUP cases were categorized as 
T0, but were not assigned to a specific anatomic subsite.  Evidence now shows that that upto 
90% of cases initially designated as having actually have virally-assciated  (HPV or EBV)  
cancers Consequently the presence of either Epstein-Barr Virus (EBV) or HPV in metastatic 
lymph nodes may facilitate identification of an anatomic site of origin [16, 17]. Therefore, at 
least p16 immunohistochemistry and EBV encoded (EBER) RNA-in situ hybridisation(ISH) are 
recommended for all cervical lymph nodes with carcinoma of unknown primary site. Thus, 
one key change from prior editions of the TNM system is the elimination of the T0 category 
in sites other than the nasopharynx, HPV–associated oropharyngeal cancer, and salivary 
gland cancers (which can be identified by histology). If no primary lesion can be identified, 
then the lymph node may have emanated from any mucosal site, so there is no rationale to 
support retaining the T0 designation outside of the virally associated cancers of the 
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oropharynx and nasopharynx[18]. In other words, when the presence of EBV RNA is 
determined by ISH, the patient is staged as per nasopharyngeal cancer, and when p16 
positive IHC is present, as per oropharyngeal cancer. In all other scenarios, the clinical and 
pathological node definitions are as per non-HPV positive oropharyngeal cancers.  
 
Presentation and clinical examination 
 
The majority of CUP patients present to the outpatient clinic with a palpable neck 
mass. This was the primary reason for consultation in 94% of a series of 352 patients [3] and 
all subjects of a separate cohort of 167 patients [1]. Other characteristic head and neck 
cancer symptoms such as dysphagia, pain and weight loss were reported in less than 10% of 
patients. Demographically, patients with CUP were typically male, between 55-65 years old 
with a history of chronic tobacco and/or alcohol use [1, 19]. More recently, this pattern 
appears to have changed with an increase in younger non-smoking patients presenting with 
human papillomavirus (HPV)-related oropharyngeal cancer [20].  
A thorough history should always be taken. This includes eliciting a history of other 
malignancies, immunosuppression or compromise, sun exposure, skin cancer or removal of 
skin lesions. This should be followed by clinical examination, which should routinely involve 
assessment of the entire upper aerodigestive tract, along with neck palpation and flexible 
nasendoscopy. Physical examination should also include skin examination. The location of 
the cervical lymph node metastasis may suggest the location of the primary site, due to 
established patterns of lymphatic drainage in the head and neck. Most commonly, enlarged 
cervical lymph nodes are identified at level II, followed by level III, with bilateral involvement 
reported in <10% [1, 3, 19]. This is in keeping with the majority of tumours in CUP patients 
being from the oropharynx. Bilateral nodal metastases should draw attention to the 
nasopharynx, base of tongue, hypopharynx and midline structures. Non-oropharyngeal 
primaries, such as skin or distant metastases from non-head and neck primary, should be 
suspected in patients with intraparotid lymph nodes or posterior or supraclavicular nodal 
involvement.   The involvement of both upper and lower nodal levels should prompt the 
physician to exclude distant metastases, which are much more frequent in these patients 
compared to the patients with involvement of just the upper nodal levels[21]. The median 
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nodal size is 3.5 to 5 cm[22]. The time interval between first appearance of a cervical mass 
and diagnosis ranged between 2 and 5 months[1, 3, 23]. 
 
 
 
Imaging 
The choice and sequence of imaging technique is important in the diagnostic workup 
of CUP. The imaging techniques utilized should be able to identify the primary site, the 
extent of nodal disease (including extranodal extension), and the presence of distant 
metastases. Computed tomography (CT) and/or Magnetic Resonance imaging (MRI) with 
intravenous contrast of the neck and thorax have been the mainstay of diagnostic workup in 
CUP detection. There appears to be no significant difference in the efficacy of CT and MRI - 
both have reported detection rates of 9-23% [24-26]. With regards to identifying 
extracapsular nodal extension, MRI is reported to be marginally superior to CT, with 
specificities and sensitivities 85% and 84% vs. 77% and 80% respectively [27]. An analysis by 
the NICE guidelines reported the pooled sensitivity of CT to detect extranodal extension in 4 
studies to be lower, at 44% (95 % confidence interval [CI] 30%, 58%) and the specificity as 
75% (95% CI 57, 88)[28].  Chai et al. report the negative predictive value of CT for the 
detection of the extranodal extension to be 49%. Therefore, CT imaging may be considered 
useful in positively identifying extracapsular extension, but not for convincingly excluding it 
[29].   
There is now a large body of evidence supporting the use of FDG-PET/CT  as an 
effective diagnostic tool for the identification of the site of the primary tumour, when 
standard imaging techniques are negative. A meta-analysis by Rusthoven et al., which 
included 302 patients from 16 studies published between 1994 and 2003, demonstrated a 
primary tumour detection rate by FDG-PET of 24.5% (sensitivity 88.3%; specificity 74.9%; 
diagnostic accuracy 78.8%)[30]. The highest false-positive rate was seen in the tonsils  
(39.3%), while the lowest sensitivity rate was seen in the base of the tongue (80.5%). A more 
recent meta-analysis by Kwee et al. using hybrid FDG-PET/CT included 11 studies published 
between 2005 and 2007 and comprised 433 patients. Here, the 
overall primary tumor detection rate, pooled sensitivity, and specificity of FDG-PET/CT/ were 
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37%, 84% (95% CI 78-88%) and 84% (95% CI 78-89%), respectively [31]. The false positive 
rate (15%) was again highest for oropharyngeal tumors.   
FDG-PET/CT scanning does have some limitations however.  The resolution of FDG-
PET/CT limits its ability to detect tumors smaller than 5mm. In addition, the basal uptake of 
FDG in normal lymphoid tissues within Waldeyer's ring and the uptake of FDG by salivary 
gland tissue limit the value of FDG-PET/CT in identifying small or superficial lesions in these 
locations. Additionally, FDG-PET/CT is relatively more expensive in comparison to 
conventional imaging modalities. In a recent study from Denmark, Dale et al. showed that 
the additional efficacy of FDG-PET/CT in identifying the primary site in patients where it has 
not been previously identified by clinical examination, flexible endoscopy, and standard 
cross-sectional imaging was only 7% (95 % CI 2–21 %). Therefore, we believe FDG-PET/CT is 
ideally indicated only when the primary site has not been identified by clinical examination 
and conventional imaging [32]. 
 
Tissue diagnosis 
 
Fine needle aspiration biopsy (FNA) is currently the most widely used technique for 
obtaining diagnostic information from metastatic lymph nodes. It is safe, cost-effective and 
reliable [33]. Excisional biopsy of lymph nodes should be avoided due to the potential local 
complications (such as hematoma, infection, disruption of fascial planes for subsequent neck 
disscetion), as well as the theoretical risk of neck recurrence [34]. However, despite certain 
advantages, FNA has also some drawbacks, especially in the setting of CUP. Cystic nodal 
metastases are particularly associated with HPV-driven malignancies[35], which are common 
causes of cup. In patients with cystic metastases, the efficacy of FNA is significantly reduced, 
with a false negative rate of up to 42% [36]. Furthermore, the differential diagnosis of a 
metastatic node includes brachial cleft cysts, a necrotic node with abscess formation or 
tuberculosis, which can sometimes be difficult to differentiate on needle aspiration alone. 
Sensitivity of this technique therefore may not exceed 50% [37], however performing FNA 
under ultrasound guidance can improve the sensitivity considerably, up to 80% [35].   
Ultrasound-guided core biopsy of the involved lymph nodes can retrieve a more 
substantial tissue sample, and is also considerably less invasive than an excisional biopsy. 
 7 
Although core biopsy may not significantly improve the overall sensitivity of diagnosing 
squamous cell carcinoma in lymph node metastases, it substantially enhances sample 
adequacy for obtaining a diagnosis. Novoa et al., in a meta-analysis and systematic review 
(16 studies, N=1267) of core needle biopsies used in the evaluation of head and neck lesions, 
showed that adequate material for histologic diagnosis and ancillary studies was obtained in 
95% of cases [38]. In some centers, a core biopsy routinely follows the FNA to enhance 
sample accuracy for HPV testing [38, 39]. Furthermore, the risk of potential complications of 
core biopsy (including tumor seeding and major bleeding) have been proven to be negligible.  
Due to these advantages, we prefer US-guided core biopsy to US-guided FNA in the 
diagnostic workup of CUP, but both are valid alternatives.   
Since up to 80% of all oropharyngeal tumors can be HPV driven malignancies, the 
determination of HPV testing in fine needle aspirates and core biopsies has gained relevance 
to guide the localization of the primary tumor[40]. The preferential distribution of p16 
staining in carcinomas of the oropharynx supports the use of p16 staining for discerning the 
site of tumor origin in those patients presenting with cervical lymph node metastases. 
Begum et al. identified HPV16 in 10 of 19 metastases from the oropharynx, but in none of 46 
metastases from other sites (53% versus 0%; P < 0.0001) [41]. p16 expression in nodal 
metastases was highly correlated with site of tumour origin.  
 Studies that have addressed HPV testing of cytological samples have primarily tried 
to adapt tissue-targeted approaches, e.g. p16 immunohistochemistry and HPV in-situ 
hybridization to cytological specimens[41, 42]. Numerous studies have confirmed the 
feasibility of p16 immunostaining in fine needle aspirates and biopsies of cervical lymph 
node metastases [41-43]. Holmes et al. [44] detected p16 staining in the FNA of involved 
nodes in 71% of the 85 patients with metastatic oropharyngeal squamous cell carcinomas. 
This is similar to the findings of other authors [41, 45]. In contrast, p16 immunostaining on 
FNA was only seen in 13% of nodal metastases from non-oropharyngeal sites (p< 0.001) [44]. 
Jakscha et al. found that in their cohort of 54 patients, p16 positivity by 
immunohistochemistry of FNA cytology correlated with that of excised lymph nodes in every 
HPV positive case [46]. Of the 17 lymph node metastases that were p16 negative on 
histology, 15 (88%) were p16-negative on FNA, and two cases were false positive. In a very 
recent study, Cheol Park et al. compared the diagnostic value of HPV, p16, and EBV in the 
aspirates from the cervical lymph nodes to FDG-PET/CT in a prospective series of 54 
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consecutive cases. Overall, primary tumors were identified in 28 (51.9%) of patients. The 
sensitivity of p16 (85.7%) and accuracy of HPV (85.2%) were higher than those of  FDG-
PET/CT (42.9% and 68.5% respectively, p < 0.05) [47]. It should be noted however that, in 
most studies, HPV testing of cytological FNA specimens was restricted to the small subset of 
the overall cases – that subset consisted of case from which sufficient cellular material was 
available for the construction of cell blocks.  For example, Begum et al. reported, that only 
20% of the FNA samples were sufficiently cellular for HPV testing [41]. Limited cellularity 
affecting p16 immunohistochemistry may also produce false negative results [44, 48, 49]. 
This further supports the superiority of core biopsies over FNA to facilitate HPV testing.   
Included in the differential diagnosis of metastatic lesions of the neck (especially 
those located in levels V, but also levels II-IV), is EBV-related, undifferentiated 
nasopharyngeal carcinoma, which should also be considered in those patients who have no 
apparent primary [50, 51]. Nakao et al. evaluated 36 nasopharyngeal cancer patients (30 
primary tumour and 6 lymph node metastases) by EBV in-situ hybridization and determined 
that 60% of primaries and 50% of metastatic cases were associated with EBV. In contrast, 
among patients with lymph nodes metastases from other head and neck sites (n=13) EBV 
was not identified in any of the cases [52]. A retrospective analysis of 22 metastatic lymph 
nodes from CUP patients attempted to determine the localization of the primary tumor by 
assessment of the HPV and EBV status in the nodes. In all 3 cases where the primary was 
eventually identified in nasopharynx, the cystic metastases turned out to be EBV positive 
and HPV negative. Where the primary originated from other anatomical site, 1 case were 
EBV positive [53]. In other consecutive series of CUP patients, oncogenic viral infections (EBV 
or HPV) were found in 12 cases (54%). In that series, EBV was detected in 2 cases  [50]. 
Therefore, for non-keratinizing or undifferentiated carcinomas that are p16 negative, EBV 
in situ hybridization (EBER) should be performed. The combination of undifferentiated 
morphology and EBV positivity is sufficient evidence to strongly suggest an occult 
nasopharyngeal primary[54]. In the newly published American Joint Cancer Commission 
(AJCC) 8th Edition TNM staging Manual  [14] and Union for International Cancer Control 
(UICC)[15], the algorithm for workup of SCC of unknown primary includes HPV and EBV 
testing. Tumours positive for the viruses are staged according to the respective staging 
criteria for oropharynx and nasopharynx (see relevant section above). 
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Panendoscopy with biopsy and tonsillectomy 
 
Regardless of the findings of the above combination of investigations, performing 
meticulous examination under anesthesia (EUA) and panendocscopy is mandatory in all CUP 
cases. Where imaging has identified the primary site, EUA allows histological confirmation by 
diagnostic biopsy. For example, Cianchetti confirmed the findings in 64% of cases where the 
index tumor had been previously identified by clinical examination and PETCT[11]. When the 
primary tumor has not been identified despite conventional and FDG-PET/CT imaging, 
subsequent EUA enabled identification of primary site in approximately  35% of patients[4, 
11]. Therefore, a negative FDG-PET/CT does not preclude the need for panendoscopy to 
detect the primary site.  In that situation, EUA should include the examination of 
nasopharynx, laryngoscopy, pharyngoscopy, and oesophagoscopy. Palpation of accessible 
subsites is also strongly advocated. Importantly, Miller also demonstrated that the overall 
risk of subsequent manifestation of a primary tumor of the upper aerodigestive tract in 
patients that have had a negative FDG-PET/CT and a negative panendoscopy was very low 
(5.8%), demonstrating the efficacy of this combined approach [4].  
Random biopsies are of very low diagnostic value [35]. In contrast, Karni found that 
undertaking transoral microscopic examination of the base of tongue identified a 
significantly higher number of primary tumors in the base of tongue compared to rigid EUA 
(94% vs. 25% respectively) [55]. Therefore, examination of the base of tongue with a 30◦ 
4mm endoscope or a microscope, in conjunction with a Feyh-Kastenbauer (FK) retractor, is 
recommended. The new generation of high and ultra-high definition systems is likely to 
assist further in this respect.  
 
Narrow band imaging 
Narrow band imaging (NBI) identifies abnormal neoangiogenic patterns on the 
mucosa. Its application in the pre-and intra-operative setting has been recently been shown 
to be an useful adjunct in the detection of primary lesion. Filauro at al. analyzed the 
consecutive case series of 29 CUP cases, where the CT and/or MRI and FDG-PET/CT did not 
reveal the primary lesion. NBI used during panendoscopy identified the primary tumor in 10 
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patients (34.5%). The sensitivity, specificity, positive and negative predictive values and 
accuracy were 91%,95%, 91%,91% and 90% respectively[56]. A pooled analysis of 5 studies 
by the NICE guidance [28] reported a pooled sensitivity and specificity of narrow band 
imaging as 77% (95 % confidence interval [CI] 50, 92) and 84% (95% CI 68, 93), respectively. 
 
Tonsillectomy 
In patients where no primary can be found on EUA, tonsillectomy is indicated. In a 
cohort of 126 patients with CUP, Walton et al. reported a positive yield in 30% of patients 
who underwent tonsillectomy. In comparison, in the same study, deep biopsies only 
identified the malignancy in 3% of cases, reflecting the fact that some tumors are small and  
located within the tonsillar crypts and so cannot be identified by simple biopsy.  While there 
are no clear recommendations available on performing unilateral or bilateral tonsillectomy, 
rates of contralateral tumours of up to 10-17% [57, 58], have been reported, suggesting a 
need for considering bilateral tonsillectomy. 
 
Tongue base mucosectomy 
In addition to tonsillectomy, there is now increasing evidence for the role of tongue 
base mucosectomy for patients whose primary remains undetected after undergoing the 
protocol described above. During this procedure, the whole of the tongue base mucosa 
(including the lingual tonsils) is removed en bloc or in two (right and left) sections. 
Meticulous histopathological examination, with multiple sections, is then undertaken. For 
example, Patel et al. performed a retrospective, multi-institutional case series, in which data 
were pooled from the 6 institutions. The primary site was located by transoral robotic 
surgery (TORS) in 34 of 47 patients (72.3%), of which the primary site was located in 
the base of tongue for 20 patients (58.8%). In 18 of 47 patients (38.3%), both preoperative 
radiographic and physical examination failed to suggest a primary site. Of these 18 patients, 
a tongue base primary as identified in 13 (72.2%) cases after undergoing TORS [59]. Similarly, 
Byrd reported identifying the primary in 19 (86.4) of the 22 cases of lingual tonsillectomy by 
TORS [60] . In another study, the average time to return to normal swallowing function was 
2.7 days, and there were no major surgical complications [61].  More recently, Winter et al., 
reported on a retrospective case review from 4 head and neck centers in the United 
Kingdom, analyzing 35 patients where the primary tumor was not identified during clinical 
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examination, imaging (including FDG-PET/CT) and bilateral tonsillectomy. The primary tumor 
site was identified in the tongue base in 53% (n=17) of patients. In 15 (88%) of these 
patients, the tumor was in the ipsilateral tongue base, while in two cases (12%) the tumor 
was located in contralateral tongue base[62]. Similar retrospective single-center analyses 
have been performed by Hatten[63] and Geltzeiler [64], who examined consecutive cohorts 
of 60 and 64 patients with unknown primary respectively. In the Hatten study, transoral 
robotic surgery procedures enabled the identification of the primary in 48 (80%) patients, all 
in the oropharynx. In 28 (50.8%) patients, the index tumor was identified in base of the 
tongue, while in 18 patients (38%) the primary tumors were in the palatine tonsils. The mean 
size of the identified mucosal primary lesions was 1.3mm (SD 0.1mm), which is below the 
resolution of detection by FDG-PET/CT. Geltzeiler reported that the primary tumor was 
found in 51 (80%) of 64 patients. Of those patients,  14 (22%) were found on EUA alone. Fifty 
patients underwent further robotic transoral lingual tonsillectomy  palatine tonsillectomy, 
with primary tumors identified in 37 (74%) cases. The primary tumor was located in 
the lingual tonsil in 32 patients (86%) and palatine tonsil in 5 patients (10%, p<0.001).  
Transoral laser microsurgery appears to be similarly effective. Karni et al.[55] 
compared transoral laser microsurgery (TLM) with traditional EUA, reporting detection rates 
of 94% compared to 25% respectively in a series of 30 patients. Nagel et al. reported a 
detection rate of 86% in a retrospective series of 36 TLM patients, using their algorithm of 
directed biopsies, frozen section, and lingual tonsillectomy [65]. 
In a very recent meta-analysis of 552 patients from 21 studies [66], the reported 
pooled rate of identification of a primary by tongue base mucosectomy was 57%. In patients 
with a negative conventional imaging, PETCTscanning, EUA and tonsillectomy, the rate of 
identification by tongue base mucosectomy rose to 78% [66]. 
The question then arises whether tonsillectomy and transoral mucosectomy should 
be performed concurrently or sequentially. Byrd et al. showed that the simultaneous 
tonsillectomy and TORS treatment strategy was associated with lower direct hospital costs 
and physician fees compared to the sequential strategy. However, simultaneous base of the 
tongue resection and tonsillectomy was associated with significantly more pain.  As a result, 
two of five patients who underwent the simultaneous procedures required longer inpatient 
stays for pain control due to inability to eat, which resulted in an increased overall cost for 
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the simultaneous strategy. There was also concern about the development of late 
circumferential stenosis, especially after radiation or concurrent chemoradiation. Overall, 
analysis of incremental cost savings for sequential and simultaneous EUA and TORS base of 
tongue resection were $8619 and $5774 respectively per additional primary identified, 
compared to EUA+ tonsillectomy alone, highlighting not only the cost-effectiveness of 
lingual tonsillectomy in this indication, but also higher cost-effectiveness of the sequential 
approach compared to concomitant procedure approach[60]. We therefore, advocate that 
delayed transoral mucosectomies are undertaken, only when the tumor remains 
unidentified after EUA and tonsillectomy.  
 
Proposed algorithm for diagnosis and treatment of CUP 
 
Based on the analysis of the above literature review, we propose an evidence-based 
algorithm for the diagnosis and management of patients presenting with clinical CUP (Fig1). 
However due to the dearth of high quality prospective or randomised data in the CUP 
setting, we have relied on data from studies of patients with known head and neck cancer 
primaries, and extrapolated this to the CUP setting. 
 
Fig. 1 The proposed diagnostic and therapeutic protocol for CUP in head and neck. 
 
For patients who present with a palpable neck mass where the primary tumor is not 
identified on clinical examination including flexible nasendoscopy (preferably with narrow 
band imaging), we recommend a CT or MRI scan of the neck, with intravenous contrast and 
a CT scan of the thorax, depending on institutional availability and waiting lists. Patients 
should also have an ultrasound-guided core biopsy (preferable to fine needle aspiration 
biopsy, albeit both are acceptable). Immunohistochemical staining of the biopsy sample for 
p16 is strongly recommended, and if negative, then EBV insitu hybridization should be 
undertaken, especially for presentations suggesting naso[haryngeal cancer. If the CT/MRI 
scan does not identify the primary site, a FDG-PET/CT scan should be requested immediately 
(preferably by the reporting radiologist) to avoid delay to further management. Requesting a 
FDG-PET/CT scan as the primary diagnostic modality is a viable alternative, and research on 
the relative cost-effectiveness of the two approaches is needed. 
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Subsequent management when the primary lesion is identified: 
 
When imaging identifies the primary lesion, EUA with directed biopsies for 
histological confirmation should be undertaken. Further management should then follow 
national and institutional guidelines. In our proposed protocol, further management is then 
determined by the status of the cervical nodal disease. If imaging detects a single node that 
is less than 3 cm in size with no extranodal extension and a resectable (T1-T2) primary 
tumor, we advocate surgical resection of the index tumor along with a neck dissection. 
Surgery is advocated in this instance due to the relatively low risk (<30%) of having 
indications for postoperative chemoradiotherapy (extranodal extension or involved 
resection margins), as demonstrated by Sinha et al [67]. We would strongly recommend a 
transoral approach, with either robotic or laser resection based on the experience of the 
surgical team, as transoral surgery has been shown to result in less gastrostomy and 
tracheostomy rates than open surgery for oropharyngeal cancer, and has been shown to be 
more cost effective[68]. On the other hand, the Sinha study [67] demonstrated that in a 
cohort of HPV+ patients undergoing TORS/TLM, 55-60% of patients with multiple nodes had 
extranodal extension. In that situation, according to current evidence [69], the patient is 
highly likely to require radiotherapy or chemoradiotherapy, despite surgical resection.  
There is some controversy regarding the significance of extranodal extension in HPV+ 
patients who are treated surgically. Sinha et al showed  that extranodal extension may not 
be an important factor, in a cohort treated with surgery and adjuvant therapy [67] 
.Furthermore, in a large follow-up study, Haughey et al [70] demonstrated that extranodal 
extension showed only a trend(HR1.6, 0.98-2.63, p=0.06) towards association  with overall 
survival, with only 100 patients. Importantly, however, they showed that post-operative 
radiotherapy (HR=0.55, p=0.033) and chemoradiotherapy (HR=0.45, p0.017) were 
significantly associated with improved survival following transoral surgery for HPV+ 
oropharyngeal cancer, highlighting the importance of adjuvant therapy in this setting. There 
are ongoing studies examining whether chemotherapy could be eliminated in patients with 
low risk HPV+OPC treated surgically and who have extracapsular spread[71, 72]. Till these 
studies report, management of extranodal extension should remain unchanged out with 
clinical trials. We therefore advocate in these cases proceeding directly to primary 
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radiotherapy or chemoradiotherapy, as this approach reduces the risk of the patient 
receiving triple therapy, with an additional (unnecessary) neck dissection and/or surgical 
excision of the primary tumor.  
 
Subsequent management when primary lesion is not identified: 
In the case that the ultrasound-guided biopsy confirms squamous cancer metastasis 
to the lymph nodes, but conventional imaging followed by FDG-PET/CT could not identify 
the site of the primary lesion, we advocate that further management should again be 
undertaken depending on the number and characteristics of the nodal disease on imaging. In 
patients with advanced neck disease, with multiple unilateral or bilateral nodal disease or 
those with extracapsular extension on imaging, but no primary site identified, tonsillectomy 
and an examination under anesthetic should be performed, along with examination of the 
tongue base using a 4mm endoscope or a microscope and narrow band imaging, as 
described above[55, 56]. If that does not identify the tumor, then performing tongue base 
mucosectomy (preferably as a separate procedure) is advised.  If no primary is identified, 
definitive treatment by chemoradiotherapy should then be considered.  Neck dissection is 
not recommended in this case, except in cases of rapidly progressive neck disease or 
genuine uncertainty regarding extracapsular spread, because as discussed previously, these 
patients have a high risk of requiring chemoradiotherapy due to extracapsular spread or 
involved margins [67]. Where no primary has been identified, panmucosal 
chemoradiotherapy should be considered. However, if the nodal disease is positive for p16 
on core biopsy and negative for EBV, then sparing of the post nasal space and larynx may be 
undertaken given the fact that a p16 positive primary is highly likely to be oropharyngeal in 
origin, as demonstrated in the studies of Begum et al.[41] Likewise, if the patient is EBV 
positive and HPV negative, radiotherapy could be directed to the nasopharynx.  
Some clinicians question the need for the tongue base mucosectomy on the basis 
that identification of a small tongue base primary may not alter management. However, on 
retrospective review of the Pittsburgh experience of 28 cases treated with TORS for 
unknown primary, Byrd et al. demonstrated the real economic value of identifying the 
primary site  – with savings of between $5774 and $8619, compared to patients where the 
primary site was not identified.[60] This is partly because a small number of patients may be 
spared radiotherapy altogether – 6% in one study [73], and moreover as Byrd study 
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demonstrates, 10 of the 19 identified primaries resected by TORS had clear margins[60].  In 
addition to the financial savings, a significant proportion of patients may benefit functionally 
from receiving radiotherapy to smaller areas of mucosa (in 46% of cases in that study), 
including sparing the contralateral tonsil, lateral constrictors and nodal structures (reported 
to take place in 30% of cases in the same study)[73]. The new consensus guidelines for 
outlining of primary tumours in HNSCC [74] , with tighter delineation of primary tumour 
Clinical Target Volumes, will likely result in further sparing of mucosa and constrictors.  
However, the clinical benefits of this approach need to be prospectively assessed and the 
contouring protocol defined, particularly given the varying use of neck dissection in 
retrospective series. 
When there is a single node measuring less than 3 cm and there is no evidence of 
extranodal extension, we advocate EUA, bilateral tonsillectomy and neck dissection 
performed at the same time. If subsequent histology confirms the presence of a tumor in the 
tonsil and no extracapsular extension is identified, transoral completion (TLM or TORS) of 
the resection is advocated, if indicated by involved resection margins and is technically 
feasible. This can  then be followed by adjuvant treatment, as determined by the standard 
indications [69]. If tonsillectomy does not identify the index malignancy, transoral 
mucosectomy of the tongue base should be undertaken.  If this is negative, then close 
follow-up with no further treatment could be considered, as in this situation the declaration 
of the primary tumor at a later date is low, reported to be only between 5.8-7%[4].  
 
 
Research 
 
Finally, it is widely acknowledged that the quality of evidence for the investigation 
and management of carcinoma of the unknown primary in the head and neck is poor, relying 
mainly on retrospective case studies, or on better quality data for the management of head 
and neck cancer with known primaries. There is an urgent need for more trials and 
prospective studies (see Table 2). Due to the relatively low numbers of cases, multicentre 
and more likely multi-national co-operative studies are likely to be required. 
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Conclusion 
 
We propose a streamlined protocol, based on currently available evidence. There is a 
dearth of evidence for carcinoma of unknown primary, and  so, where there is a lack of 
evidence,  we have relied on evidence from studies of patients with identified primary 
tumours. Trials or well-designed prospective studies are urgently needed to examine the 
long term efficacy and functional outcomes of different combinations and sequences of 
investigations and treatment modalities for CUP.  
 
Table1: Sensitivity and specificity of different investigations from meta-analyses studies 
 
Investigation type 
(reference) 
Sensitivity (95 % CI) Specificity (95 % CI) Primary detection 
rate 
CT scan for 
extranodal 
extension [28] 
44% (30%, 58%)  75% (57, 88) N/A 
Narrow band 
imaging [30]28] 
77% (50, 92)  84% (68, 93) N/A 
PET CT [30], [31] 88.3% 
84% (78-88%) 
74.9% 
84% (78-89%) 
24.5% 
37% 
Tongue base 
mucosectomy [66] 
- - 78% 
 
Key: 
confidence interval =CI 
 
Table 2: 
Potential research questions: 
What is the efficacy and cost-effectiveness of different sequences of investigations to detect 
the primary site? Especially does starting with conventional imaging better and more cost 
effective than starting with PET CT?  
Does doing a tongue base mucosectomy to identify the site of the primary result in 
additional, functional quality of life or other benefits in patients who are going to be treated 
with radical chemoradiotherapy anyway? And is it cost-effective? 
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Does extranodal extension in patients with HPV+ CUP behave differently to that in patients 
with HPV-negative CUP? 
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An evidence-based approach to the investigation and management of squamous cell 
carcinoma occult primary tumors of the head and neck. 
 
 
 
 
Abstract: 
 
Metastases to the cervical lymph nodes from a occult primary (CUP) of head and neck 
squamous carcinomas has been increasing in presentation (HNSCC). Modern diagnostic 
workup, including clinical evaluation, conventional imaging, FDG-PET/CT and 
panendoscopy/tonsillectomy enables detection of the primary site in over half of all cases, 
and is associated with significantly improved survival rates. Recent studies have 
demonstrated the utility of novel molecular pathology and transoral surgical techniques in 
improving diagnosis and treatment. We present a new, evidence-based protocol 
incorporating these novel diagnostic modalities. It aims to identify the site of the primary 
tumor, and determine the stage of the disease, including extranodal extension. This 
information can personalise treatment recommendations, rationalise combinations of 
treatment modalities, and thereby potentially minimise toxicity and improving functional 
outcomes.  
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Introduction 
 
The carcinoma of unknown primary in the head and neck (CUP) occurs when a 
patient presents with clinically-evident cervical lymphadenopathy, but where a primary 
tumor cannot be identified by thorough medical history, clinical examination and non-
invasive and invasive diagnostic workup [1]. 
The identification of the primary site by modern functional imaging has significantly 
reduced the prevalence of true CUP [2]. In the past, only about 1-7% of all head and neck 
cancer patients present with metastases to the lymph nodes as the only clinical evidence of 
the disease [3-5]. This appears to be is increasing in incidence due to the increasing human 
papillomavirus-related oropharyngeal cancer [5]. The natural history of the development of 
CUP remains unclear. Potential reasons for the inability to detect the primary site may 
include small tumour volume, hidden location (e.g. tonsillar crypt), slow growth rate, and/or 
possible involution of the primary tumor, thereby hindering its recognition[6, 7].  
Several guidelines, consensus statements, and literature reviews have been 
published describing the diagnostic and therapeutic approach to CUP in the last decade [8-
10]. However, recently there has been a considerable amount of new and essential data 
published on novel diagnostic approaches, including the role of Human papillomavirus (HPV) 
detection and the utility of transoral minimally-invasive procedures. Our aim here is to 
present an evidence-based algorithm for the diagnosis and treatment of patients with CUP, 
that incorporates recent developments. 
 
Objectives: 
 
The principal objectives of the diagnostic evaluation of the patient with CUP are to 
identify the location of the primary tumor, to reliably determine the histology, to ascertain 
the extent of locoregional disease (including nodal extranodal extension), and to exclude 
distant metastases. The other important consideration for the diagnostic workup should be 
the utilization of the shortest and the least invasive pathway to achieve diagnosis and 
treatment, with the least morbidity and the highest cost-effectiveness [9].  
A retrospective study of 236 patients with an initial presentation of CUP 
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demonstrated ultimate detection of a primary tumour after investigation in 53% of cases.  
Approximately 88% of these were oropharyngeal primaries (equally divided between the 
base of tongue and tonsil). The likelihood of a biopsy-proven primary decreased significantly 
in patients with no findings on examination and radiology, compared to those with positive 
findings on both (29% vs. 64% respectively)[11].  
Identification of the primary site is crucial as it helps direct therapy and has been 
reported by some studies to be associated with better prognosis and survival.  A matched 
paired retrospective analysis by Davis  (n=22), demonstrated significantly improved survival 
in patients with CUP where the primary tumour was subsequently identified, compared to 
those where it was not (HR = 0.125; 95% CI, 0.019–0.822; P = .030). This may be in part 
because lesions that were identified were more likely to be HPV positive[12]. Similarly, Haas 
et al. reported 100% 3-year survival in the eight patients whose oropharyngeal primary was 
identified compared to 58.8% for the 34 patients with a persistent "occult primary" (n=34) 
[13].  
 
TNM staging: 
 
In the American Joint Cancer Commission (AJCC) [14] and Union for International 
Cancer Control (UICC) 8th Editipn TNM Staging Manual [15], substantial changes have been 
introduced to the staging of patients with  CUP.  Previously, CUP cases were categorized as 
T0, but were not assigned to a specific anatomic subsite.  Evidence now shows that that upto 
90% of cases initially designated as having actually have virally-assciated  (HPV or EBV)  
cancers Consequently the presence of either Epstein-Barr Virus (EBV) or HPV in metastatic 
lymph nodes may facilitate identification of an anatomic site of origin [16, 17]. Therefore, at 
least p16 immunohistochemistry and EBV encoded (EBER) RNA-in situ hybridisation(ISH) are 
recommended for all cervical lymph nodes with carcinoma of unknown primary site. Thus, 
one key change from prior editions of the TNM system is the elimination of the T0 category 
in sites other than the nasopharynx, HPV–associated oropharyngeal cancer, and salivary 
gland cancers (which can be identified by histology). If no primary lesion can be identified, 
then the lymph node may have emanated from any mucosal site, so there is no rationale to 
support retaining the T0 designation outside of the virally associated cancers of the 
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oropharynx and nasopharynx[18]. In other words, when the presence of EBV RNA is 
determined by ISH, the patient is staged as per nasopharyngeal cancer, and when p16 
positive IHC is present, as per oropharyngeal cancer. In all other scenarios, the clinical and 
pathological node definitions are as per non-HPV positive oropharyngeal cancers.  
 
Presentation and clinical examination 
 
The majority of CUP patients present to the outpatient clinic with a palpable neck 
mass. This was the primary reason for consultation in 94% of a series of 352 patients [3] and 
all subjects of a separate cohort of 167 patients [1]. Other characteristic head and neck 
cancer symptoms such as dysphagia, pain and weight loss were reported in less than 10% of 
patients. Demographically, patients with CUP were typically male, between 55-65 years old 
with a history of chronic tobacco and/or alcohol use [1, 19]. More recently, this pattern 
appears to have changed with an increase in younger non-smoking patients presenting with 
human papillomavirus (HPV)-related oropharyngeal cancer [20].  
A thorough history should always be taken. This includes eliciting a history of other 
malignancies, immunosuppression or compromise, sun exposure, skin cancer or removal of 
skin lesions. This should be followed by clinical examination, which should routinely involve 
assessment of the entire upper aerodigestive tract, along with neck palpation and flexible 
nasendoscopy. Physical examination should also include skin examination. The location of 
the cervical lymph node metastasis may suggest the location of the primary site, due to 
established patterns of lymphatic drainage in the head and neck. Most commonly, enlarged 
cervical lymph nodes are identified at level II, followed by level III, with bilateral involvement 
reported in <10% [1, 3, 19]. This is in keeping with the majority of tumours in CUP patients 
being from the oropharynx. Bilateral nodal metastases should draw attention to the 
nasopharynx, base of tongue, hypopharynx and midline structures. Non-oropharyngeal 
primaries, such as skin or distant metastases from non-head and neck primary, should be 
suspected in patients with intraparotid lymph nodes or posterior or supraclavicular nodal 
involvement.   The involvement of both upper and lower nodal levels should prompt the 
physician to exclude distant metastases, which are much more frequent in these patients 
compared to the patients with involvement of just the upper nodal levels[21]. The median 
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nodal size is 3.5 to 5 cm[22]. The time interval between first appearance of a cervical mass 
and diagnosis ranged between 2 and 5 months[1, 3, 23]. 
 
 
 
Imaging 
The choice and sequence of imaging technique is important in the diagnostic workup 
of CUP. The imaging techniques utilized should be able to identify the primary site, the 
extent of nodal disease (including extranodal extension), and the presence of distant 
metastases. Computed tomography (CT) and/or Magnetic Resonance imaging (MRI) with 
intravenous contrast of the neck and thorax have been the mainstay of diagnostic workup in 
CUP detection. There appears to be no significant difference in the efficacy of CT and MRI - 
both have reported detection rates of 9-23% [24-26]. With regards to identifying 
extracapsular nodal extension, MRI is reported to be marginally superior to CT, with 
specificities and sensitivities 85% and 84% vs. 77% and 80% respectively [27]. An analysis by 
the NICE guidelines reported the pooled sensitivity of CT to detect extranodal extension in 4 
studies to be lower, at 44% (95 % confidence interval [CI] 30%, 58%) and the specificity as 
75% (95% CI 57, 88)[28].  Chai et al. report the negative predictive value of CT for the 
detection of the extranodal extension to be 49%. Therefore, CT imaging may be considered 
useful in positively identifying extracapsular extension, but not for convincingly excluding it 
[29].   
There is now a large body of evidence supporting the use of FDG-PET/CT  as an 
effective diagnostic tool for the identification of the site of the primary tumour, when 
standard imaging techniques are negative. A meta-analysis by Rusthoven et al., which 
included 302 patients from 16 studies published between 1994 and 2003, demonstrated a 
primary tumour detection rate by FDG-PET of 24.5% (sensitivity 88.3%; specificity 74.9%; 
diagnostic accuracy 78.8%)[30]. The highest false-positive rate was seen in the tonsils  
(39.3%), while the lowest sensitivity rate was seen in the base of the tongue (80.5%). A more 
recent meta-analysis by Kwee et al. using hybrid FDG-PET/CT included 11 studies published 
between 2005 and 2007 and comprised 433 patients. Here, the 
overall primary tumor detection rate, pooled sensitivity, and specificity of FDG-PET/CT/ were 
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37%, 84% (95% CI 78-88%) and 84% (95% CI 78-89%), respectively [31]. The false positive 
rate (15%) was again highest for oropharyngeal tumors.   
FDG-PET/CT scanning does have some limitations however.  The resolution of FDG-
PET/CT limits its ability to detect tumors smaller than 5mm. In addition, the basal uptake of 
FDG in normal lymphoid tissues within Waldeyer's ring and the uptake of FDG by salivary 
gland tissue limit the value of FDG-PET/CT in identifying small or superficial lesions in these 
locations. Additionally, FDG-PET/CT is relatively more expensive in comparison to 
conventional imaging modalities. In a recent study from Denmark, Dale et al. showed that 
the additional efficacy of FDG-PET/CT in identifying the primary site in patients where it has 
not been previously identified by clinical examination, flexible endoscopy, and standard 
cross-sectional imaging was only 7% (95 % CI 2–21 %). Therefore, we believe FDG-PET/CT is 
ideally indicated only when the primary site has not been identified by clinical examination 
and conventional imaging [32]. 
 
Tissue diagnosis 
 
Fine needle aspiration biopsy (FNA) is currently the most widely used technique for 
obtaining diagnostic information from metastatic lymph nodes. It is safe, cost-effective and 
reliable [33]. Excisional biopsy of lymph nodes should be avoided due to the potential local 
complications (such as hematoma, infection, disruption of fascial planes for subsequent neck 
disscetion), as well as the theoretical risk of neck recurrence [34]. However, despite certain 
advantages, FNA has also some drawbacks, especially in the setting of CUP. Cystic nodal 
metastases are particularly associated with HPV-driven malignancies[35], which are common 
causes of cup. In patients with cystic metastases, the efficacy of FNA is significantly reduced, 
with a false negative rate of up to 42% [36]. Furthermore, the differential diagnosis of a 
metastatic node includes brachial cleft cysts, a necrotic node with abscess formation or 
tuberculosis, which can sometimes be difficult to differentiate on needle aspiration alone. 
Sensitivity of this technique therefore may not exceed 50% [37], however performing FNA 
under ultrasound guidance can improve the sensitivity considerably, up to 80% [35].   
Ultrasound-guided core biopsy of the involved lymph nodes can retrieve a more 
substantial tissue sample, and is also considerably less invasive than an excisional biopsy. 
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Although core biopsy may not significantly improve the overall sensitivity of diagnosing 
squamous cell carcinoma in lymph node metastases, it substantially enhances sample 
adequacy for obtaining a diagnosis. Novoa et al., in a meta-analysis and systematic review 
(16 studies, N=1267) of core needle biopsies used in the evaluation of head and neck lesions, 
showed that adequate material for histologic diagnosis and ancillary studies was obtained in 
95% of cases [38]. In some centers, a core biopsy routinely follows the FNA to enhance 
sample accuracy for HPV testing [38, 39]. Furthermore, the risk of potential complications of 
core biopsy (including tumor seeding and major bleeding) have been proven to be negligible.  
Due to these advantages, we prefer US-guided core biopsy to US-guided FNA in the 
diagnostic workup of CUP, but both are valid alternatives.   
Since up to 80% of all oropharyngeal tumors can be HPV driven malignancies, the 
determination of HPV testing in fine needle aspirates and core biopsies has gained relevance 
to guide the localization of the primary tumor[40]. The preferential distribution of p16 
staining in carcinomas of the oropharynx supports the use of p16 staining for discerning the 
site of tumor origin in those patients presenting with cervical lymph node metastases. 
Begum et al. identified HPV16 in 10 of 19 metastases from the oropharynx, but in none of 46 
metastases from other sites (53% versus 0%; P < 0.0001) [41]. p16 expression in nodal 
metastases was highly correlated with site of tumour origin.  
 Studies that have addressed HPV testing of cytological samples have primarily tried 
to adapt tissue-targeted approaches, e.g. p16 immunohistochemistry and HPV in-situ 
hybridization to cytological specimens[41, 42]. Numerous studies have confirmed the 
feasibility of p16 immunostaining in fine needle aspirates and biopsies of cervical lymph 
node metastases [41-43]. Holmes et al. [44] detected p16 staining in the FNA of involved 
nodes in 71% of the 85 patients with metastatic oropharyngeal squamous cell carcinomas. 
This is similar to the findings of other authors [41, 45]. In contrast, p16 immunostaining on 
FNA was only seen in 13% of nodal metastases from non-oropharyngeal sites (p< 0.001) [44]. 
Jakscha et al. found that in their cohort of 54 patients, p16 positivity by 
immunohistochemistry of FNA cytology correlated with that of excised lymph nodes in every 
HPV positive case [46]. Of the 17 lymph node metastases that were p16 negative on 
histology, 15 (88%) were p16-negative on FNA, and two cases were false positive. In a very 
recent study, Cheol Park et al. compared the diagnostic value of HPV, p16, and EBV in the 
aspirates from the cervical lymph nodes to FDG-PET/CT in a prospective series of 54 
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consecutive cases. Overall, primary tumors were identified in 28 (51.9%) of patients. The 
sensitivity of p16 (85.7%) and accuracy of HPV (85.2%) were higher than those of  FDG-
PET/CT (42.9% and 68.5% respectively, p < 0.05) [47]. It should be noted however that, in 
most studies, HPV testing of cytological FNA specimens was restricted to the small subset of 
the overall cases – that subset consisted of case from which sufficient cellular material was 
available for the construction of cell blocks.  For example, Begum et al. reported, that only 
20% of the FNA samples were sufficiently cellular for HPV testing [41]. Limited cellularity 
affecting p16 immunohistochemistry may also produce false negative results [44, 48, 49]. 
This further supports the superiority of core biopsies over FNA to facilitate HPV testing.   
Included in the differential diagnosis of metastatic lesions of the neck (especially 
those located in levels V, but also levels II-IV), is EBV-related, undifferentiated 
nasopharyngeal carcinoma, which should also be considered in those patients who have no 
apparent primary [50, 51]. Nakao et al. evaluated 36 nasopharyngeal cancer patients (30 
primary tumour and 6 lymph node metastases) by EBV in-situ hybridization and determined 
that 60% of primaries and 50% of metastatic cases were associated with EBV. In contrast, 
among patients with lymph nodes metastases from other head and neck sites (n=13) EBV 
was not identified in any of the cases [52]. A retrospective analysis of 22 metastatic lymph 
nodes from CUP patients attempted to determine the localization of the primary tumor by 
assessment of the HPV and EBV status in the nodes. In all 3 cases where the primary was 
eventually identified in nasopharynx, the cystic metastases turned out to be EBV positive 
and HPV negative. Where the primary originated from other anatomical site, 1 case were 
EBV positive [53]. In other consecutive series of CUP patients, oncogenic viral infections (EBV 
or HPV) were found in 12 cases (54%). In that series, EBV was detected in 2 cases  [50]. 
Therefore, for non-keratinizing or undifferentiated carcinomas that are p16 negative, EBV 
in situ hybridization (EBER) should be performed. The combination of undifferentiated 
morphology and EBV positivity is sufficient evidence to strongly suggest an occult 
nasopharyngeal primary[54]. In the newly published American Joint Cancer Commission 
(AJCC) 8th Edition TNM staging Manual  [14] and Union for International Cancer Control 
(UICC)[15], the algorithm for workup of SCC of unknown primary includes HPV and EBV 
testing. Tumours positive for the viruses are staged according to the respective staging 
criteria for oropharynx and nasopharynx (see relevant section above). 
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Panendoscopy with biopsy and tonsillectomy 
 
Regardless of the findings of the above combination of investigations, performing 
meticulous examination under anesthesia (EUA) and panendocscopy is mandatory in all CUP 
cases. Where imaging has identified the primary site, EUA allows histological confirmation by 
diagnostic biopsy. For example, Cianchetti confirmed the findings in 64% of cases where the 
index tumor had been previously identified by clinical examination and PETCT[11]. When the 
primary tumor has not been identified despite conventional and FDG-PET/CT imaging, 
subsequent EUA enabled identification of primary site in approximately  35% of patients[4, 
11]. Therefore, a negative FDG-PET/CT does not preclude the need for panendoscopy to 
detect the primary site.  In that situation, EUA should include the examination of 
nasopharynx, laryngoscopy, pharyngoscopy, and oesophagoscopy. Palpation of accessible 
subsites is also strongly advocated. Importantly, Miller also demonstrated that the overall 
risk of subsequent manifestation of a primary tumor of the upper aerodigestive tract in 
patients that have had a negative FDG-PET/CT and a negative panendoscopy was very low 
(5.8%), demonstrating the efficacy of this combined approach [4].  
Random biopsies are of very low diagnostic value [35]. In contrast, Karni found that 
undertaking transoral microscopic examination of the base of tongue identified a 
significantly higher number of primary tumors in the base of tongue compared to rigid EUA 
(94% vs. 25% respectively) [55]. Therefore, examination of the base of tongue with a 30◦ 
4mm endoscope or a microscope, in conjunction with a Feyh-Kastenbauer (FK) retractor, is 
recommended. The new generation of high and ultra-high definition systems is likely to 
assist further in this respect.  
 
Narrow band imaging 
Narrow band imaging (NBI) identifies abnormal neoangiogenic patterns on the 
mucosa. Its application in the pre-and intra-operative setting has been recently been shown 
to be an useful adjunct in the detection of primary lesion. Filauro at al. analyzed the 
consecutive case series of 29 CUP cases, where the CT and/or MRI and FDG-PET/CT did not 
reveal the primary lesion. NBI used during panendoscopy identified the primary tumor in 10 
 10 
patients (34.5%). The sensitivity, specificity, positive and negative predictive values and 
accuracy were 91%,95%, 91%,91% and 90% respectively[56]. A pooled analysis of 5 studies 
by the NICE guidance [28] reported a pooled sensitivity and specificity of narrow band 
imaging as 77% (95 % confidence interval [CI] 50, 92) and 84% (95% CI 68, 93), respectively. 
 
Tonsillectomy 
In patients where no primary can be found on EUA, tonsillectomy is indicated. In a 
cohort of 126 patients with CUP, Walton et al. reported a positive yield in 30% of patients 
who underwent tonsillectomy. In comparison, in the same study, deep biopsies only 
identified the malignancy in 3% of cases, reflecting the fact that some tumors are small and  
located within the tonsillar crypts and so cannot be identified by simple biopsy.  While there 
are no clear recommendations available on performing unilateral or bilateral tonsillectomy, 
rates of contralateral tumours of up to 10-17% [57, 58], have been reported, suggesting a 
need for considering bilateral tonsillectomy. 
 
Tongue base mucosectomy 
In addition to tonsillectomy, there is now increasing evidence for the role of tongue 
base mucosectomy for patients whose primary remains undetected after undergoing the 
protocol described above. During this procedure, the whole of the tongue base mucosa 
(including the lingual tonsils) is removed en bloc or in two (right and left) sections. 
Meticulous histopathological examination, with multiple sections, is then undertaken. For 
example, Patel et al. performed a retrospective, multi-institutional case series, in which data 
were pooled from the 6 institutions. The primary site was located by transoral robotic 
surgery (TORS) in 34 of 47 patients (72.3%), of which the primary site was located in 
the base of tongue for 20 patients (58.8%). In 18 of 47 patients (38.3%), both preoperative 
radiographic and physical examination failed to suggest a primary site. Of these 18 patients, 
a tongue base primary as identified in 13 (72.2%) cases after undergoing TORS [59]. Similarly, 
Byrd reported identifying the primary in 19 (86.4) of the 22 cases of lingual tonsillectomy by 
TORS [60] . In another study, the average time to return to normal swallowing function was 
2.7 days, and there were no major surgical complications [61].  More recently, Winter et al., 
reported on a retrospective case review from 4 head and neck centers in the United 
Kingdom, analyzing 35 patients where the primary tumor was not identified during clinical 
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examination, imaging (including FDG-PET/CT) and bilateral tonsillectomy. The primary tumor 
site was identified in the tongue base in 53% (n=17) of patients. In 15 (88%) of these 
patients, the tumor was in the ipsilateral tongue base, while in two cases (12%) the tumor 
was located in contralateral tongue base[62]. Similar retrospective single-center analyses 
have been performed by Hatten[63] and Geltzeiler [64], who examined consecutive cohorts 
of 60 and 64 patients with unknown primary respectively. In the Hatten study, transoral 
robotic surgery procedures enabled the identification of the primary in 48 (80%) patients, all 
in the oropharynx. In 28 (50.8%) patients, the index tumor was identified in base of the 
tongue, while in 18 patients (38%) the primary tumors were in the palatine tonsils. The mean 
size of the identified mucosal primary lesions was 1.3mm (SD 0.1mm), which is below the 
resolution of detection by FDG-PET/CT. Geltzeiler reported that the primary tumor was 
found in 51 (80%) of 64 patients. Of those patients,  14 (22%) were found on EUA alone. Fifty 
patients underwent further robotic transoral lingual tonsillectomy  palatine tonsillectomy, 
with primary tumors identified in 37 (74%) cases. The primary tumor was located in 
the lingual tonsil in 32 patients (86%) and palatine tonsil in 5 patients (10%, p<0.001).  
Transoral laser microsurgery appears to be similarly effective. Karni et al.[55] 
compared transoral laser microsurgery (TLM) with traditional EUA, reporting detection rates 
of 94% compared to 25% respectively in a series of 30 patients. Nagel et al. reported a 
detection rate of 86% in a retrospective series of 36 TLM patients, using their algorithm of 
directed biopsies, frozen section, and lingual tonsillectomy [65]. 
In a very recent meta-analysis of 552 patients from 21 studies [66], the reported 
pooled rate of identification of a primary by tongue base mucosectomy was 57%. In patients 
with a negative conventional imaging, PETCTscanning, EUA and tonsillectomy, the rate of 
identification by tongue base mucosectomy rose to 78% [66]. 
The question then arises whether tonsillectomy and transoral mucosectomy should 
be performed concurrently or sequentially. Byrd et al. showed that the simultaneous 
tonsillectomy and TORS treatment strategy was associated with lower direct hospital costs 
and physician fees compared to the sequential strategy. However, simultaneous base of the 
tongue resection and tonsillectomy was associated with significantly more pain.  As a result, 
two of five patients who underwent the simultaneous procedures required longer inpatient 
stays for pain control due to inability to eat, which resulted in an increased overall cost for 
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the simultaneous strategy. There was also concern about the development of late 
circumferential stenosis, especially after radiation or concurrent chemoradiation. Overall, 
analysis of incremental cost savings for sequential and simultaneous EUA and TORS base of 
tongue resection were $8619 and $5774 respectively per additional primary identified, 
compared to EUA+ tonsillectomy alone, highlighting not only the cost-effectiveness of 
lingual tonsillectomy in this indication, but also higher cost-effectiveness of the sequential 
approach compared to concomitant procedure approach[60]. We therefore, advocate that 
delayed transoral mucosectomies are undertaken, only when the tumor remains 
unidentified after EUA and tonsillectomy.  
 
Proposed algorithm for diagnosis and treatment of CUP 
 
Based on the analysis of the above literature review, we propose an evidence-based 
algorithm for the diagnosis and management of patients presenting with clinical CUP (Fig1). 
However due to the dearth of high quality prospective or randomised data in the CUP 
setting, we have relied on data from studies of patients with known head and neck cancer 
primaries, and extrapolated this to the CUP setting. 
 
Fig. 1 The proposed diagnostic and therapeutic protocol for CUP in head and neck. 
 
For patients who present with a palpable neck mass where the primary tumor is not 
identified on clinical examination including flexible nasendoscopy (preferably with narrow 
band imaging), we recommend a CT or MRI scan of the neck, with intravenous contrast and 
a CT scan of the thorax, depending on institutional availability and waiting lists. Patients 
should also have an ultrasound-guided core biopsy (preferable to fine needle aspiration 
biopsy, albeit both are acceptable). Immunohistochemical staining of the biopsy sample for 
p16 is strongly recommended, and if negative, then EBV insitu hybridization should be 
undertaken, especially for presentations suggesting naso[haryngeal cancer. If the CT/MRI 
scan does not identify the primary site, a FDG-PET/CT scan should be requested immediately 
(preferably by the reporting radiologist) to avoid delay to further management. Requesting a 
FDG-PET/CT scan as the primary diagnostic modality is a viable alternative, and research on 
the relative cost-effectiveness of the two approaches is needed. 
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Subsequent management when the primary lesion is identified: 
 
When imaging identifies the primary lesion, EUA with directed biopsies for 
histological confirmation should be undertaken. Further management should then follow 
national and institutional guidelines. In our proposed protocol, further management is then 
determined by the status of the cervical nodal disease. If imaging detects a single node that 
is less than 3 cm in size with no extranodal extension and a resectable (T1-T2) primary 
tumor, we advocate surgical resection of the index tumor along with a neck dissection. 
Surgery is advocated in this instance due to the relatively low risk (<30%) of having 
indications for postoperative chemoradiotherapy (extranodal extension or involved 
resection margins), as demonstrated by Sinha et al [67]. We would strongly recommend a 
transoral approach, with either robotic or laser resection based on the experience of the 
surgical team, as transoral surgery has been shown to result in less gastrostomy and 
tracheostomy rates than open surgery for oropharyngeal cancer, and has been shown to be 
more cost effective[68]. On the other hand, the Sinha study [67] demonstrated that in a 
cohort of HPV+ patients undergoing TORS/TLM, 55-60% of patients with multiple nodes had 
extranodal extension. In that situation, according to current evidence [69], the patient is 
highly likely to require radiotherapy or chemoradiotherapy, despite surgical resection.  
There is some controversy regarding the significance of extranodal extension in HPV+ 
patients who are treated surgically. Sinha et al showed  that extranodal extension may not 
be an important factor, in a cohort treated with surgery and adjuvant therapy [67] 
.Furthermore, in a large follow-up study, Haughey et al [70] demonstrated that extranodal 
extension showed only a trend(HR1.6, 0.98-2.63, p=0.06) towards association  with overall 
survival, with only 100 patients. Importantly, however, they showed that post-operative 
radiotherapy (HR=0.55, p=0.033) and chemoradiotherapy (HR=0.45, p0.017) were 
significantly associated with improved survival following transoral surgery for HPV+ 
oropharyngeal cancer, highlighting the importance of adjuvant therapy in this setting. There 
are ongoing studies examining whether chemotherapy could be eliminated in patients with 
low risk HPV+OPC treated surgically and who have extracapsular spread[71, 72]. Till these 
studies report, management of extranodal extension should remain unchanged out with 
clinical trials. We therefore advocate in these cases proceeding directly to primary 
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radiotherapy or chemoradiotherapy, as this approach reduces the risk of the patient 
receiving triple therapy, with an additional (unnecessary) neck dissection and/or surgical 
excision of the primary tumor.  
 
Subsequent management when primary lesion is not identified: 
In the case that the ultrasound-guided biopsy confirms squamous cancer metastasis 
to the lymph nodes, but conventional imaging followed by FDG-PET/CT could not identify 
the site of the primary lesion, we advocate that further management should again be 
undertaken depending on the number and characteristics of the nodal disease on imaging. In 
patients with advanced neck disease, with multiple unilateral or bilateral nodal disease or 
those with extracapsular extension on imaging, but no primary site identified, tonsillectomy 
and an examination under anesthetic should be performed, along with examination of the 
tongue base using a 4mm endoscope or a microscope and narrow band imaging, as 
described above[55, 56]. If that does not identify the tumor, then performing tongue base 
mucosectomy (preferably as a separate procedure) is advised.  If no primary is identified, 
definitive treatment by chemoradiotherapy should then be considered.  Neck dissection is 
not recommended in this case, except in cases of rapidly progressive neck disease or 
genuine uncertainty regarding extracapsular spread, because as discussed previously, these 
patients have a high risk of requiring chemoradiotherapy due to extracapsular spread or 
involved margins [67]. Where no primary has been identified, panmucosal 
chemoradiotherapy should be considered. However, if the nodal disease is positive for p16 
on core biopsy and negative for EBV, then sparing of the post nasal space and larynx may be 
undertaken given the fact that a p16 positive primary is highly likely to be oropharyngeal in 
origin, as demonstrated in the studies of Begum et al.[41] Likewise, if the patient is EBV 
positive and HPV negative, radiotherapy could be directed to the nasopharynx.  
Some clinicians question the need for the tongue base mucosectomy on the basis 
that identification of a small tongue base primary may not alter management. However, on 
retrospective review of the Pittsburgh experience of 28 cases treated with TORS for 
unknown primary, Byrd et al. demonstrated the real economic value of identifying the 
primary site  – with savings of between $5774 and $8619, compared to patients where the 
primary site was not identified.[60] This is partly because a small number of patients may be 
spared radiotherapy altogether – 6% in one study [73], and moreover as Byrd study 
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demonstrates, 10 of the 19 identified primaries resected by TORS had clear margins[60].  In 
addition to the financial savings, a significant proportion of patients may benefit functionally 
from receiving radiotherapy to smaller areas of mucosa (in 46% of cases in that study), 
including sparing the contralateral tonsil, lateral constrictors and nodal structures (reported 
to take place in 30% of cases in the same study)[73]. The new consensus guidelines for 
outlining of primary tumours in HNSCC [74] , with tighter delineation of primary tumour 
Clinical Target Volumes, will likely result in further sparing of mucosa and constrictors.  
However, the clinical benefits of this approach need to be prospectively assessed and the 
contouring protocol defined, particularly given the varying use of neck dissection in 
retrospective series. 
When there is a single node measuring less than 3 cm and there is no evidence of 
extranodal extension, we advocate EUA, bilateral tonsillectomy and neck dissection 
performed at the same time. If subsequent histology confirms the presence of a tumor in the 
tonsil and no extracapsular extension is identified, transoral completion (TLM or TORS) of 
the resection is advocated, if indicated by involved resection margins and is technically 
feasible. This can  then be followed by adjuvant treatment, as determined by the standard 
indications [69]. If tonsillectomy does not identify the index malignancy, transoral 
mucosectomy of the tongue base should be undertaken.  If this is negative, then close 
follow-up with no further treatment could be considered, as in this situation the declaration 
of the primary tumor at a later date is low, reported to be only between 5.8-7%[4].  
 
 
Research 
 
Finally, it is widely acknowledged that the quality of evidence for the investigation 
and management of carcinoma of the unknown primary in the head and neck is poor, relying 
mainly on retrospective case studies, or on better quality data for the management of head 
and neck cancer with known primaries. There is an urgent need for more trials and 
prospective studies (see Table 2). Due to the relatively low numbers of cases, multicentre 
and more likely multi-national co-operative studies are likely to be required. 
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Conclusion 
 
We propose a streamlined protocol, based on currently available evidence. There is a 
dearth of evidence for carcinoma of unknown primary, and  so, where there is a lack of 
evidence,  we have relied on evidence from studies of patients with identified primary 
tumours. Trials or well-designed prospective studies are urgently needed to examine the 
long term efficacy and functional outcomes of different combinations and sequences of 
investigations and treatment modalities for CUP.  
 
Table1: Sensitivity and specificity of different investigations from meta-analyses studies 
 
Investigation type 
(reference) 
Sensitivity (95 % CI) Specificity (95 % CI) Primary detection 
rate 
CT scan for 
extranodal 
extension [28] 
44% (30%, 58%)  75% (57, 88) N/A 
Narrow band 
imaging [30]28] 
77% (50, 92)  84% (68, 93) N/A 
PET CT [30], [31] 88.3% 
84% (78-88%) 
74.9% 
84% (78-89%) 
24.5% 
37% 
Tongue base 
mucosectomy [66] 
- - 78% 
 
Key: 
confidence interval =CI 
 
Table 2: 
Potential research questions: 
What is the efficacy and cost-effectiveness of different sequences of investigations to detect 
the primary site? Especially does starting with conventional imaging better and more cost 
effective than starting with PET CT?  
Does doing a tongue base mucosectomy to identify the site of the primary result in 
additional, functional quality of life or other benefits in patients who are going to be treated 
with radical chemoradiotherapy anyway? And is it cost-effective? 
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Does extranodal extension in patients with HPV+ CUP behave differently to that in patients 
with HPV-negative CUP? 
 
 
References: 
[1] Issing WJ, Taleban B, Tauber S. Diagnosis and management of carcinoma of unknown 
primary in the head and neck. Eur Arch Otorhinolaryngol. 2003;260:436-43. 
[2] Johansen J, Buus S, Loft A, Keiding S, Overgaard M, Hansen HS, et al. Prospective study of 
18FDG-PET in the detection and management of patients with lymph node metastases to 
the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck. 
2008;30:471-8. 
[3] Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node 
metastases from unknown primary tumours. Results from a national survey by the Danish 
Society for Head and Neck Oncology. Radiother Oncol. 2000;55:121-9. 
[4] Miller FR, Karnad AB, Eng T, Hussey DH, Stan McGuff H, Otto RA. Management of the 
unknown primary carcinoma: long-term follow-up on a negative PET scan and negative 
panendoscopy. Head Neck. 2008;30:28-34. 
[5] Galloway TJ, Ridge JA. Management of Squamous Cancer Metastatic to Cervical Nodes 
With an Unknown Primary Site. J Clin Oncol. 2015;33:3328-37. 
[6] van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown 
primary tumour: a literature review. Ann Oncol. 2003;14:191-6. 
[7] Califano J, Westra WH, Koch W, Meininger G, Reed A, Yip L, et al. Unknown primary head 
and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl 
Cancer Inst. 1999;91:599-604. 
[8] Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al. Head and Neck 
Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015;13:847-55; quiz 56. 
[9] Mackenzie K, Watson M, Jankowska P, Bhide S, Simo R. Investigation and management of 
the unknown primary with metastatic neck disease: United Kingdom National 
Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S170-S5. 
[10] Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et al. Cancers of 
unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol. 2015;26 Suppl 5:v133-8. 
[11] Cianchetti M, Mancuso AA, Amdur RJ, Werning JW, Kirwan J, Morris CG, et al. Diagnostic 
evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown 
head and neck primary site. Laryngoscope. 2009;119:2348-54. 
[12] Davis KS, Byrd JK, Mehta V, Chiosea SI, Kim S, Ferris RL, et al. Occult Primary Head and 
Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions. Otolaryngol Head 
Neck Surg. 2014;151:272-8. 
[13] Haas I, Hoffmann TK, Engers R, Ganzer U. Diagnostic strategies in cervical carcinoma of 
an unknown primary (CUP). Eur Arch Otorhinolaryngol. 2002;259:325-33. 
[14] Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The 
Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-
based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67:93-9. 
 18 
[15] Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, et al. Eighth Edition of 
the UICC Classification of Malignant Tumours: an overview of the changes in the pathological 
TNM classification criteria-What has changed and why? Virchows Arch. 2017. 
[16] Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, et al. p16 status, 
pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in 
head and neck squamous cell carcinomas of unknown primary. Head Neck. 2014;36:1677-84. 
[17] Mirzamani N, Salehian P, Farhadi M, Tehran EA. Detection of EBV and HPV in 
nasopharyngeal carcinoma by in situ hybridization. Exp Mol Pathol. 2006;81:231-4. 
[18] Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and 
Neck cancers-major changes in the American Joint Committee on cancer eighth edition 
cancer staging manual. CA Cancer J Clin. 2017;67:122-37. 
[19] Aslani M, Sultanem K, Voung T, Hier M, Niazi T, Shenouda G. Metastatic carcinoma to 
the cervical nodes from an unknown head and neck primary site: Is there a need for neck 
dissection? Head Neck. 2007;29:585-90. 
[20] D'Souza G, Zhang HH, D'Souza WD, Meyer RR, Gillison ML. Moderate predictive value of 
demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-
negative head and neck cancer. Oral Oncol. 2010;46:100-4. 
[21] Strojan P, Ferlito A, Medina JE, Woolgar JA, Rinaldo A, Robbins KT, et al. Contemporary 
management of lymph node metastases from an unknown primary to the neck: I. A review 
of diagnostic approaches. Head Neck. 2013;35:123-32. 
[22] Boscolo-Rizzo P, Da Mosto MC, Gava A, Marchiori C. Cervical lymph node metastases 
from occult squamous cell carcinoma: analysis of 82 cases. ORL J Otorhinolaryngol Relat 
Spec. 2006;68:189-94. 
[23] Nguyen C, Shenouda G, Black MJ, Vuong T, Donath D, Yassa M. Metastatic squamous 
cell carcinoma to cervical lymph nodes from unknown primary mucosal sites. Head Neck. 
1994;16:58-63. 
[24] Waltonen JD, Ozer E, Hall NC, Schuller DE, Agrawal A. Metastatic carcinoma of the neck 
of unknown primary origin: evolution and efficacy of the modern workup. Arch Otolaryngol 
Head Neck Surg. 2009;135:1024-9. 
[25] Freudenberg LS, Fischer M, Antoch G, Jentzen W, Gutzeit A, Rosenbaum SJ, et al. Dual 
modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography 
in patients with cervical carcinoma of unknown primary. Med Princ Pract. 2005;14:155-60. 
[26] Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, et al. Detection 
of unknown primary tumours and distant metastases in patients with cervical metastases: 
value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging. 
2002;29:1024-30. 
[27] Su Z, Duan Z, Pan W, Wu C, Jia Y, Han B, et al. Predicting extracapsular spread of head 
and neck cancers using different imaging techniques: a systematic review and meta-analysis. 
Int J Oral Maxillofac Surg. 2016;45:413-21. 
[28] Cancer of the Upper Aerodigestive Tract: Assessment and Management in People Aged 
16 and Over. London2016. 
[29] Chai RL, Rath TJ, Johnson JT, Ferris RL, Kubicek GJ, Duvvuri U, et al. Accuracy of 
computed tomography in the prediction of extracapsular spread of lymph node metastases 
in squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg. 
2013;139:1187-94. 
 19 
[30] Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission 
tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 
2004;101:2641-9. 
[31] Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary 
tumors: systematic review and meta-analysis. Eur Radiol. 2009;19:731-44. 
[32] Dale E, Moan JM, Osnes TA, Bogsrud TV. Cervical lymph node metastases of squamous 
cell carcinoma of unknown origin: the diagnostic value of FDG PET/CT and clinical outcome. 
Eur Arch Otorhinolaryngol. 2017;274:1015-9. 
[33] Layfield LJ. Fine-needle aspiration in the diagnosis of head and neck lesions: a review 
and discussion of problems in differential diagnosis. Diagn Cytopathol. 2007;35:798-805. 
[34] Martin JM, Galloway TJ. Evaluation and management of head and neck squamous cell 
carcinoma of unknown primary. Surg Oncol Clin N Am. 2015;24:579-91. 
[35] Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI, et al. Cystic lymph node 
metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head 
Neck. 2008;30:898-903. 
[36] Gourin CG, Johnson JT. Incidence of unsuspected metastases in lateral cervical cysts. 
Laryngoscope. 2000;110:1637-41. 
[37] Pisharodi LR. False-negative diagnosis in fine-needle aspirations of squamous-cell 
carcinoma of head and neck. Diagn Cytopathol. 1997;17:70-3. 
[38] Novoa E, Gurtler N, Arnoux A, Kraft M. Role of ultrasound-guided core-needle biopsy in 
the assessment of head and neck lesions: a meta-analysis and systematic review of the 
literature. Head Neck. 2012;34:1497-503. 
[39] Witt BL, Schmidt RL. Ultrasound-guided core needle biopsy of salivary gland lesions: a 
systematic review and meta-analysis. Laryngoscope. 2014;124:695-700. 
[40] Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a 
causal association between human papillomavirus and a subset of head and neck cancers. J 
Natl Cancer Inst. 2000;92:709-20. 
[41] Begum S, Gillison ML, Nicol TL, Westra WH. Detection of human papillomavirus-16 in 
fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell 
carcinoma of the head and neck. Clin Cancer Res. 2007;13:1186-91. 
[42] Zhang MQ, El-Mofty SK, Davila RM. Detection of human papillomavirus-related 
squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration 
biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck 
primary. Cancer. 2008;114:118-23. 
[43] Umudum H, Rezanko T, Dag F, Dogruluk T. Human papillomavirus genome detection by 
in situ hybridization in fine-needle aspirates of metastatic lesions from head and neck 
squamous cell carcinomas. Cancer. 2005;105:171-7. 
[44] Holmes BJ, Maleki Z, Westra WH. The Fidelity of p16 Staining as a Surrogate Marker of 
Human Papillomavirus Status in Fine-Needle Aspirates and Core Biopsies of Neck Node 
Metastases: Implications for HPV Testing Protocols. Acta Cytol. 2015;59:97-103. 
[45] Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human 
papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor 
origin. Clin Cancer Res. 2003;9:6469-75. 
[46] Jakscha J, Zlobec I, Storck C, Obermann EC, Tornillo L, Terracciano LM, et al. The clinical 
impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and 
neck squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2013;270:661-7. 
 20 
[47] Cheol Park G, Roh JL, Cho KJ, Seung Kim J, Hyeon Jin M, Choi SH, et al. 18 F-FDG PET/CT 
vs. human papillomavirus, p16 and Epstein-Barr virus detection in cervical metastatic lymph 
nodes for identifying primary tumors. Int J Cancer. 2017;140:1405-12. 
[48] Jalaly JB, Lewis JS, Jr., Collins BT, Wu X, Ma XJ, Luo Y, et al. Correlation of p16 
immunohistochemistry in FNA biopsies with corresponding tissue specimens in HPV-related 
squamous cell carcinomas of the oropharynx. Cancer Cytopathol. 2015;123:723-31. 
[49] Xu B, Ghossein R, Lane J, Lin O, Katabi N. The utility of p16 immunostaining in fine 
needle aspiration in p16-positive head and neck squamous cell carcinoma. Hum Pathol. 
2016;54:193-200. 
[50] Bussu F, Sali M, Gallus R, Petrone G, Autorino R, Santangelo R, et al. HPV and EBV 
Infections in Neck Metastases from Occult Primary Squamous Cell Carcinoma: Another Virus-
Related Neoplastic Disease in the Head and Neck Region. Ann Surg Oncol. 2015;22 Suppl 
3:S979-84. 
[51] Tong CC, Luk MY, Chow SM, Ngan KC, Lau WH. Cervical nodal metastases from occult 
primary: undifferentiated carcinoma versus squamous cell carcinoma. Head Neck. 
2002;24:361-9. 
[52] Nakao K, Yuge T, Mochiki M, Nibu K, Sugasawa M. Detection of Epstein-Barr virus in 
metastatic lymph nodes of patients with nasopharyngeal carcinoma and a primary unknown 
carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:338-40. 
[53] Svajdler M, Jr., Kaspirkova J, Hadravsky L, Laco J, Dubinsky P, Straka L, et al. Origin of 
cystic squamous cell carcinoma metastases in head and neck lymph nodes: Addition of EBV 
testing improves diagnostic accuracy. Pathol Res Pract. 2016;212:524-31. 
[54] Katabi N, Lewis JS. Update from the 4th Edition of the World Health Organization 
Classification of Head and Neck Tumours: What Is New in the 2017 WHO Blue Book for 
Tumors and Tumor-Like Lesions of the Neck and Lymph Nodes. Head Neck Pathol. 
2017;11:48-54. 
[55] Karni RJ, Rich JT, Sinha P, Haughey BH. Transoral laser microsurgery: a new approach for 
unknown primaries of the head and neck. Laryngoscope. 2011;121:1194-201. 
[56] Filauro M, Paderno A, Perotti P, Marchi F, Garofolo S, Peretti G, et al. Role of narrow-
band imaging in detection of head and neck unknown primary squamous cell carcinoma. 
Laryngoscope. 2018. 
[57] Durmus K, Rangarajan SV, Old MO, Agrawal A, Teknos TN, Ozer E. Transoral robotic 
approach to carcinoma of unknown primary. Head Neck. 2014;36:848-52. 
[58] Koch WM, Bhatti N, Williams MF, Eisele DW. Oncologic rationale for bilateral 
tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. 
Otolaryngol Head Neck Surg. 2001;124:331-3. 
[59] Patel SA, Magnuson JS, Holsinger FC, Karni RJ, Richmon JD, Gross ND, et al. Robotic 
surgery for primary head and neck squamous cell carcinoma of unknown site. JAMA 
Otolaryngol Head Neck Surg. 2013;139:1203-11. 
[60] Byrd JK, Smith KJ, de Almeida JR, Albergotti WG, Davis KS, Kim SW, et al. Transoral 
Robotic Surgery and the Unknown Primary: A Cost-Effectiveness Analysis. Otolaryngol Head 
Neck Surg. 2014;150:976-82. 
[61] Krishnan S, Connell J, Ofo E. Transoral robotic surgery base of tongue mucosectomy for 
head and neck cancer of unknown primary. ANZ J Surg. 2016. 
[62] Winter SC, Ofo E, Meikle D, Silva P, Fraser L, O'Hara J, et al. Trans-oral robotic assisted 
tongue base mucosectomy for investigation of cancer of unknown primary in the head and 
neck region. The UK experience. Clin Otolaryngol. 2017. 
 21 
[63] Hatten KM, O'Malley BW, Jr., Bur AM, Patel MR, Rassekh CH, Newman JG, et al. 
Transoral Robotic Surgery-Assisted Endoscopy With Primary Site Detection and Treatment in 
Occult Mucosal Primaries. JAMA Otolaryngol Head Neck Surg. 2017;143:267-73. 
[64] Geltzeiler M, Doerfler S, Turner M, Albergotti WG, Kubik M, Kim S, et al. Transoral 
robotic surgery for management of cervical unknown primary squamous cell carcinoma: 
Updates on efficacy, surgical technique and margin status. Oral Oncol. 2017;66:9-13. 
[65] Nagel TH, Hinni ML, Hayden RE, Lott DG. Transoral laser microsurgery for the unknown 
primary: role for lingual tonsillectomy. Head Neck. 2014;36:942-6. 
[66] Farooq S ,Khandavilli S, Dretzke J, Moore D, Nankivell PC, de Almeida JR et al. Transoral 
tongue base mucosectomy for the identification of the primary site in cancers of unknown 
origin: Systematic review and meta-analysis. 
Oral Oncology, submitted.  
[67] Sinha P, Lewis JS, Jr., Piccirillo JF, Kallogjeri D, Haughey BH. Extracapsular spread and 
adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. 
Cancer. 2012;118:3519-30. 
[68] Motz K, Chang HY, Quon H, Richmon J, Eisele DW, Gourin CG. Association of Transoral 
Robotic Surgery With Short-term and Long-term Outcomes and Costs of Care in 
Oropharyngeal Cancer Surgery. JAMA Otolaryngol Head Neck Surg. 2017;143:580-8. 
[69] Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer 
patients: how strong is the evidence? Oncologist. 2005;10:215-24. 
[70] Haughey BH, Sinha P, Kallogjeri D, Goldberg RL, Lewis JS, Jr., Piccirillo JF, et al. 
Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral 
Oncol. 2016;62:11-9. 
[71] Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-
related, p16+ Oropharynx Cancer. 
[72] Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS). 
[73] Patel SA, Parvathaneni A, Parvathaneni U, Houlton JJ, Karni RJ, Liao JJ, et al. Post-
operative therapy following transoral robotic surgery for unknown primary cancers of the 
head and neck. Oral Oncol. 2017;72:150-6. 
[74] Gregoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the 
primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, 
oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, 
GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, 
PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 
2018;126:3-24. 
 
 
Figure 1
Click here to download high resolution image
